MT-2111 (loncastuximab tesirine-lpyl) achieved primary endpoint in phase 2 part of Japanese phase 1/2 study for relapsed or refractory Diffuse Large B-cell Lymphoma

CAR-T Digest - August 2020

Weekly Digest - January 2026

29 January 2026: MT-2111 (loncastuximab tesirine-lpyl) achieved primary endpoint in phase 2 part of Japanese phase 1/2 study for relapsed or refractory Diffuse Large B-cell Lymphoma

Tanabe Pharma announced a key clinical advance in Japan, revealing that MT-2111, also known as loncastuximab tesirine-lpyl (ZYNLONTA®), met its primary endpoint of overall response rate in the Phase 2 portion of a Japanese Phase 1/2 study involving patients with relapsed or refractory diffuse large B-cell lymphoma, a population with few remaining treatment options
This outcome gains additional weight as the Japanese trial was designed as a bridging study to the global pivotal LOTIS-2 program led by ADC Therapeutics, with safety results in Japanese patients aligning closely with those seen in overseas studies, reinforcing the consistency of the therapy’s clinical profile
Reflecting on the milestone, Tanabe Pharma highlighted that the positive data stem from sustained research efforts and close collaboration with partners, noting that the results bring renewed hope to patients while strengthening the company’s resolve to work closely with regulators to accelerate access
From the global partner’s perspective, ADC Therapeutics emphasized that the Japanese data further validate the strength of ZYNLONTA® in difficult-to-treat DLBCL, marking another step toward expanding availability of this CD19-targeted ADC to more relapsed and refractory patients worldwide
With ZYNLONTA® already holding accelerated approval in the U.S. and conditional approval in Europe, Tanabe Pharma now plans to file a new drug application in Japan based on the MT-2111-A-101 results alongside global data, underscoring its growing commitment to oncology and its ambition to deliver new treatment options for patients facing aggressive blood cancers